BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 9819502)

  • 21. Correlations of morphology, proliferation indices, and oncogene activation in ductal breast carcinoma: nuclear grade, S-phase, proliferating cell nuclear antigen, p53, epidermal growth factor receptor, and c-erb-B-2.
    Dabbs DJ
    Mod Pathol; 1995 Aug; 8(6):637-42. PubMed ID: 8532697
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours.
    Jaros E; Perry RH; Adam L; Kelly PJ; Crawford PJ; Kalbag RM; Mendelow AD; Sengupta RP; Pearson AD
    Br J Cancer; 1992 Aug; 66(2):373-85. PubMed ID: 1503912
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas.
    Peraud A; Kreth FW; Wiestler OD; Kleihues P; Reulen HJ
    Clin Cancer Res; 2002 May; 8(5):1117-24. PubMed ID: 12006527
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship of p53 and c-erbB-2 expression to histopathological features, Helicobacter pylori infection and prognosis in gastric cancer.
    Shun CT; Wu MS; Lin JT; Chen SY; Wang HP; Lee WJ; Wang TH; Chuang SM
    Hepatogastroenterology; 1997; 44(14):604-9. PubMed ID: 9164544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic impact of p53, c-erbB-2 and epidermal growth factor receptor on head and neck carcinoma.
    Parise Junior O; Carvalho LV; Miguel RE; Kowalski LP
    Sao Paulo Med J; 2004 Nov; 122(6):264-8. PubMed ID: 15692721
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pathologic significance of proliferative activity and oncoprotein expression in astrocytic tumors.
    Bian XW; Shi JQ; Liu FX
    Anal Quant Cytol Histol; 2000 Dec; 22(6):429-37. PubMed ID: 11147296
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of immunohistochemical staining for proliferating cell nuclear antigen, p53, and c-erbB-2 in sebaceous gland carcinoma and sweat gland carcinoma: comparison with histopathological parameter.
    Hasebe T; Mukai K; Yamaguchi N; Ishihara K; Kaneko A; Takasaki Y; Shimosato Y
    Mod Pathol; 1994 Jan; 7(1):37-43. PubMed ID: 7909154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survivin subcellular localization in high-grade astrocytomas: simultaneous expression in both nucleus and cytoplasm is negative prognostic marker.
    Saito T; Arifin MT; Hama S; Kajiwara Y; Sugiyama K; Yamasaki F; Hidaka T; Arita K; Kurisu K
    J Neurooncol; 2007 Apr; 82(2):193-8. PubMed ID: 17151933
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunohistochemical analysis of metallothionein in astrocytic tumors in relation to tumor grade, proliferative potential, and survival.
    Hiura T; Khalid H; Yamashita H; Tokunaga Y; Yasunaga A; Shibata S
    Cancer; 1998 Dec; 83(11):2361-9. PubMed ID: 9840536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and immunohistochemical prognostic factors in adult glioblastoma patients.
    Umesh S; Tandon A; Santosh V; Anandh B; Sampath S; Chandramouli BA; Sastry Kolluri VR
    Clin Neuropathol; 2009; 28(5):362-72. PubMed ID: 19788052
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic value of the combination of epidermal growth factor receptor and c-erbB-2 in breast cancer.
    Tsutsui S; Ohno S; Murakami S; Kataoka A; Kinoshita J; Hachitanda Y
    Surgery; 2003 Feb; 133(2):219-21. PubMed ID: 12605184
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation among six biologic factors (p53, p21(WAF1), MIB-1, EGFR, HER2, and Bcl-2) and clinical outcomes after curative chemoradiation therapy in squamous cell cervical cancer.
    Yamashita H; Murakami N; Asari T; Okuma K; Ohtomo K; Nakagawa K
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1165-72. PubMed ID: 19101092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor, and c-erbB-2 in early cervical squamous cell carcinoma. An immunohistochemical study.
    Kristensen GB; Holm R; Abeler VM; Tropé CG
    Cancer; 1996 Aug; 78(3):433-40. PubMed ID: 8697388
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of molecular markers in low-grade diffuse astrocytomas: loss of p16 and retinoblastoma protein expression is associated with short survival.
    Hilton DA; Penney M; Evans B; Sanders H; Love S
    Am J Surg Pathol; 2002 Apr; 26(4):472-8. PubMed ID: 11914625
    [TBL] [Abstract][Full Text] [Related]  

  • 35. c-erbB-2 in astrocytomas: infrequent overexpression by immunohistochemistry and absence of gene amplification by fluorescence in situ hybridization.
    Haapasalo H; Hyytinen E; Sallinen P; Helin H; Kallioniemi OP; Isola J
    Br J Cancer; 1996 Mar; 73(5):620-3. PubMed ID: 8605096
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group.
    Chakravarti A; Winter K; Wu CL; Kaufman D; Hammond E; Parliament M; Tester W; Hagan M; Grignon D; Heney N; Pollack A; Sandler H; Shipley W
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):309-17. PubMed ID: 15890569
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of gemistocytes in astrocytoma progression.
    Watanabe K; Tachibana O; Yonekawa Y; Kleihues P; Ohgaki H
    Lab Invest; 1997 Feb; 76(2):277-84. PubMed ID: 9042164
    [TBL] [Abstract][Full Text] [Related]  

  • 38. p53 protein and epidermal growth factor receptor expression in human astrocytomas.
    Kordek R; Biernat W; Alwasiak J; Maculewicz R; Yanagihara R; Liberski PP
    J Neurooncol; 1995 Oct; 26(1):11-6. PubMed ID: 8583240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic indicators in a range of astrocytic tumours: an immunohistochemical study with Ki-67 and p53 antibodies.
    Ellison DW; Steart PV; Bateman AC; Pickering RM; Palmer JD; Weller RO
    J Neurol Neurosurg Psychiatry; 1995 Oct; 59(4):413-9. PubMed ID: 7561922
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of proliferation markers and p53 expression in gliomas of astrocytic origin: relationships and prognostic value.
    Cunningham JM; Kimmel DW; Scheithauer BW; O'Fallon JR; Novotny PJ; Jenkins RB
    J Neurosurg; 1997 Jan; 86(1):121-30. PubMed ID: 8988090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.